Creative medical technology files orphan drug designation application with the u.s. fda using the immcelz® platform for the treatment of brittle type 1 diabetes

Phoenix, march 23, 2023 /prnewswire/ -- creative medical technology holdings, inc. (nasdaq: celz), a biotechnology company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today announced that it filed an application with the u.s. food and drug administration (fda) to receive orphan drug designation (odd) for the treatment of brittle type 1 diabetes using its immcelz®(celz-100) platform. the immcelz® (celz-100) immunotherapy product utilizes the  company's cell-free system which has previously been validated to supercharge the patient's own cells to treat a number of immune disorders.
CELZ Ratings Summary
CELZ Quant Ranking